Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Thu, 16.03.2023
Evotec SE
KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS
PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC
Hamburg, Germany, 16 March 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic p [ … ]
Thu, 16.03.2023
Evotec SE
KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS
PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC
Hamburg, Germany, 16 March 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic p [ … ]
Fri, 10.02.2023
Evotec SE
FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD® TOULOUSE, FRANCE (EU)
FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017
UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLANS OF EVOTEC
TRANSACTION TO BE SIGNED BY EVOTEC’S MANAGEMENT AND EIB VICE PR [ … ]
Fri, 10.02.2023
Evotec SE
FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD® TOULOUSE, FRANCE (EU)
FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017
UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLANS OF EVOTEC
TRANSACTION TO BE SIGNED BY EVOTEC’S MANAGEMENT AND EIB VICE PR [ … ]
Thu, 09.02.2023
Evotec SE
EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES
THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES
EXTENSION AND EXPANSION THROUGH 2030 TO INCLUDE EVOTEC’S INDUSTRY-LEADING CAPABILITIES IN THE DISCOVERY OF CO [ … ]
Thu, 09.02.2023
Evotec SE
EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES
THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES
EXTENSION AND EXPANSION THROUGH 2030 TO INCLUDE EVOTEC’S INDUSTRY-LEADING CAPABILITIES IN THE DISCOVERY OF CO [ … ]
Tue, 07.02.2023
Evotec SE
Hamburg, Germany, 07 February 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023. She will take over from Enno Spillner whose contract [ … ]
Tue, 07.02.2023
Evotec SE
Hamburg, Germany, 07 February 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023. She will take over from Enno Spillner whose contract [ … ]
Thu, 26.01.2023
Evotec SE
STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT
Hamburg, Germany, 26 January 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotec [ … ]
Fri, 16.12.2022
Evotec SE
EQS-Media / 16.12.2022 / 07:30 CET/CEST
THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT
EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB
Hamburg, Germany, 16 December 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE00056 [ … ]